Promising prostate cancer combo study pulled before it started
NCT ID NCT06528210
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study aimed to see if adding the immunotherapy drug pembrolizumab to standard hormone therapy and radiation could improve outcomes for men with high-risk prostate cancer that hasn't spread. It was designed for adults with newly diagnosed, localized disease. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.